Avacopan Improves Kidney Health in ANCA-Associated Vasculitis with eGFRs Less than 20
Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.
New York United States Frank Cortazar Silbersteinn Chemocentryx Study Group Rare Diseases Information Center
Source: hcplive.com